Alnylam Pharmaceuticals Inc revenue growth has been varied year-over-year.

What is ALNY's revenue growth rate?

Historical revenue data is available for Alnylam Pharmaceuticals Inc to analyze growth trends.

How fast is ALNY earnings growing?

Earnings growth data is available for Alnylam Pharmaceuticals Inc analysis.

What is ALNY's profit margin?

Profit margin data is available for Alnylam Pharmaceuticals Inc.

ALNY Revenue & Earnings Growth Analysis 2026 - Is Alnylam Pharmaceuticals Inc Growing?

Growth Summary

Alnylam Pharmaceuticals Inc (ALNY) has experienced challenges in growth. The company operates in the Healthcare sector, specifically in the Biotechnology industry.

Over the past 4 years, Alnylam Pharmaceuticals Inc has achieved a revenue compound annual growth rate (CAGR) of 46.1%, while earnings have grown at -24.5% CAGR.

Latest Revenue

$2.25B

Net Income

$-278157000.00

5-Year Revenue CAGR

46.1%

4 years of data

Net Margin

N/A

Latest period

Revenue Growth Over Time

Historical revenue and profitability trends for Alnylam Pharmaceuticals Inc

The chart above illustrates Alnylam Pharmaceuticals Inc's revenue trajectory over the past 4 years. The revenue pattern shows the challenges the company has faced in recent periods.

Year-over-Year Growth Rates

Annual percentage change in revenue and earnings

Growth rates provide insight into the momentum of Alnylam Pharmaceuticals Inc's business.

Profit Margin Trends

How efficiently Alnylam Pharmaceuticals Inc converts revenue into profit

Understanding Profit Margins

Profit margins reveal how much of each dollar of revenue Alnylam Pharmaceuticals Inc retains at different stages:

Gross Margin (N/A%): What remains after direct production costs
Operating Margin (N/A%): Profit from core operations before interest and taxes
Net Margin (N/A%): Final profit after all expenses

Future Growth Outlook

Analyst estimates and forward-looking indicators

EPS Estimate 2026

$9.24

Current: $-2.18

EPS Estimate 2027

$14.12

52.7% expected growth

Price Target

$448.92

Analyst consensus

What Analysts Are Saying

Wall Street analysts project Alnylam Pharmaceuticals Inc to continue growing earnings in the coming year. The consensus analyst rating is 4 based on 33 analysts.

Growth Analysis Conclusion

Based on our comprehensive analysis, Alnylam Pharmaceuticals Inc (ALNY) demonstrates declining growth characteristics.

Key Takeaways:

Revenue Growth:, 46.1% CAGR over 4 years
Profitability: shows the company is investing in growth over short-term profits
Efficiency:

Investment Considerations

This growth analysis provides a comprehensive view of Alnylam Pharmaceuticals Inc's historical performance and future outlook. Investors should consider these growth metrics alongside valuation, competitive positioning, and broader market conditions when making investment decisions. Past performance does not guarantee future results.